Neurology: Randomized, Dose-ranging Safety Trial of Cannabidiol in Dravet Syndrome

CME : 0.75
Start Date :  Apr 03, 2018End Date :  Apr 03, 2021

Organized by :   American Academy of Neurology (AAN)

Specialties :   Neurology

Fees Fee :   Free

Conference Summary

Neurology: Randomized, Dose-ranging Safety Trial of Cannabidiol in Dravet Syndrome is organized by American Academy of Neurology (AAN) and will be held from Apr 03, 2018 - Apr 03, 2021. This CME Conference has been approved for a maximum of 0.75 AMA PRA Category 1 Credits

Learning Objectives:
• Upon completion of the article by Devinsky et al, the participant should be able to:
• Briefly describe the pharmacokinetic profile of cannabidiol over the range of doses tested in this study
• State the effect of cannabidiol exposure in this study on the serum levels of other anticonvulsants and anticonvulsant metabolites
• Discuss the most common adverse effects seen with cannabidiol administration during this study

Additional details will be posted as soon as they are available.

Credit Info

  • CME : 0.75
Contact Us

Toll free Number

1(800) 826-2059

Email

support@eMedEvents.com

Chat Assistant

Live Chat
Recommended